Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer

Amanda Psyrri, Mohamad Kassar, Ziwei Yu, Aris Bamias, Paul Maurice Weinberger, Sonia Markakis, Diane Kowalski, Robert L. Camp, David L. Rimm, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background: Several lines of laboratory evidence support the epidermal growth factor receptor (EGFR) as an adverse prognostic indicator in ovarian cancers. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of EGFR protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). Results: Mean follow-up time for the entire cohort was 34.4 months. Eighty-one of 150 cases had sufficient tissue for AQUA analysis. High tumor EGFR expression was associated with poor outcome for overall survival (P = 0.0001) and disease-free survival (P = 0.0005) at 3 years. In multivariable analysis, adjusting for well-characterized prognostic variables, EGFR expression status was the most significant prognostic factor for disease-free and overall survival. Conclusion: The conflicting results in the literature regarding the prognostic value of EGFR may be due to the technical difficulties inherent in assessing EGFR with immunocytochemistry. In the present study, we show that measurement of EGFR protein levels in ovarian cancer using AQUA is feasible and can give important prognostic information.

Original languageEnglish (US)
Pages (from-to)8637-8643
Number of pages7
JournalClinical Cancer Research
Volume11
Issue number24
DOIs
StatePublished - Dec 15 2005

Fingerprint

Epidermal Growth Factor Receptor
Survival
Ovarian Neoplasms
Disease-Free Survival
Proteins
Ovarian epithelial cancer
Paclitaxel
Combination Drug Therapy
Platinum
Fluorescent Antibody Technique
Immunohistochemistry
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Psyrri, A., Kassar, M., Yu, Z., Bamias, A., Weinberger, P. M., Markakis, S., ... Dimopoulos, M. A. (2005). Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clinical Cancer Research, 11(24), 8637-8643. https://doi.org/10.1158/1078-0432.CCR-05-1436

Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. / Psyrri, Amanda; Kassar, Mohamad; Yu, Ziwei; Bamias, Aris; Weinberger, Paul Maurice; Markakis, Sonia; Kowalski, Diane; Camp, Robert L.; Rimm, David L.; Dimopoulos, Meletios A.

In: Clinical Cancer Research, Vol. 11, No. 24, 15.12.2005, p. 8637-8643.

Research output: Contribution to journalArticle

Psyrri, A, Kassar, M, Yu, Z, Bamias, A, Weinberger, PM, Markakis, S, Kowalski, D, Camp, RL, Rimm, DL & Dimopoulos, MA 2005, 'Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer', Clinical Cancer Research, vol. 11, no. 24, pp. 8637-8643. https://doi.org/10.1158/1078-0432.CCR-05-1436
Psyrri, Amanda ; Kassar, Mohamad ; Yu, Ziwei ; Bamias, Aris ; Weinberger, Paul Maurice ; Markakis, Sonia ; Kowalski, Diane ; Camp, Robert L. ; Rimm, David L. ; Dimopoulos, Meletios A. / Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 24. pp. 8637-8643.
@article{29abadd9d87e4f6985d2fbbcac919a52,
title = "Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer",
abstract = "Background: Several lines of laboratory evidence support the epidermal growth factor receptor (EGFR) as an adverse prognostic indicator in ovarian cancers. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of EGFR protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). Results: Mean follow-up time for the entire cohort was 34.4 months. Eighty-one of 150 cases had sufficient tissue for AQUA analysis. High tumor EGFR expression was associated with poor outcome for overall survival (P = 0.0001) and disease-free survival (P = 0.0005) at 3 years. In multivariable analysis, adjusting for well-characterized prognostic variables, EGFR expression status was the most significant prognostic factor for disease-free and overall survival. Conclusion: The conflicting results in the literature regarding the prognostic value of EGFR may be due to the technical difficulties inherent in assessing EGFR with immunocytochemistry. In the present study, we show that measurement of EGFR protein levels in ovarian cancer using AQUA is feasible and can give important prognostic information.",
author = "Amanda Psyrri and Mohamad Kassar and Ziwei Yu and Aris Bamias and Weinberger, {Paul Maurice} and Sonia Markakis and Diane Kowalski and Camp, {Robert L.} and Rimm, {David L.} and Dimopoulos, {Meletios A.}",
year = "2005",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1436",
language = "English (US)",
volume = "11",
pages = "8637--8643",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer

AU - Psyrri, Amanda

AU - Kassar, Mohamad

AU - Yu, Ziwei

AU - Bamias, Aris

AU - Weinberger, Paul Maurice

AU - Markakis, Sonia

AU - Kowalski, Diane

AU - Camp, Robert L.

AU - Rimm, David L.

AU - Dimopoulos, Meletios A.

PY - 2005/12/15

Y1 - 2005/12/15

N2 - Background: Several lines of laboratory evidence support the epidermal growth factor receptor (EGFR) as an adverse prognostic indicator in ovarian cancers. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of EGFR protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). Results: Mean follow-up time for the entire cohort was 34.4 months. Eighty-one of 150 cases had sufficient tissue for AQUA analysis. High tumor EGFR expression was associated with poor outcome for overall survival (P = 0.0001) and disease-free survival (P = 0.0005) at 3 years. In multivariable analysis, adjusting for well-characterized prognostic variables, EGFR expression status was the most significant prognostic factor for disease-free and overall survival. Conclusion: The conflicting results in the literature regarding the prognostic value of EGFR may be due to the technical difficulties inherent in assessing EGFR with immunocytochemistry. In the present study, we show that measurement of EGFR protein levels in ovarian cancer using AQUA is feasible and can give important prognostic information.

AB - Background: Several lines of laboratory evidence support the epidermal growth factor receptor (EGFR) as an adverse prognostic indicator in ovarian cancers. However, different methods of immunohistochemical assessment have yielded conflicting results. Here, we sought to determine the prognostic value of EGFR in ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers uniformly treated, with surgical debulking followed by platinum-paclitaxel combination chemotherapy, was constructed. For evaluation of EGFR protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis (AQUA). Results: Mean follow-up time for the entire cohort was 34.4 months. Eighty-one of 150 cases had sufficient tissue for AQUA analysis. High tumor EGFR expression was associated with poor outcome for overall survival (P = 0.0001) and disease-free survival (P = 0.0005) at 3 years. In multivariable analysis, adjusting for well-characterized prognostic variables, EGFR expression status was the most significant prognostic factor for disease-free and overall survival. Conclusion: The conflicting results in the literature regarding the prognostic value of EGFR may be due to the technical difficulties inherent in assessing EGFR with immunocytochemistry. In the present study, we show that measurement of EGFR protein levels in ovarian cancer using AQUA is feasible and can give important prognostic information.

UR - http://www.scopus.com/inward/record.url?scp=29344462994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344462994&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1436

DO - 10.1158/1078-0432.CCR-05-1436

M3 - Article

VL - 11

SP - 8637

EP - 8643

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -